Canopy Growth Corp
CGC evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CGC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CGC
Canopy Growth Corp is a world-leading cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products, with a focus on the Canadian and international markets.
Key risk: Regulatory and legal risks
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 clinical trial · 1 catalyst for Canopy Growth Corp.
Canopy Growth Corp is a world-leading cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products, with a focus on the Canadian and international markets.
- Canopy Growth is a world-leading cannabis company producing, distributing, and selling a diverse range of cannabis and cannabis-related products [sec_mda · as of 2026-02-06].
- As of 2026-06-30, the company reported cash & equivalents of $336.6M, total revenue of $100.4M, net income of -$14.6M, shareholders' equity of $697.6M, and total debt of $269.0M [sec].
- The company operates in industries involving risks and uncertainties subject to change based on various factors, including regulatory and economic conditions [sec_mda · as of 2026-08-07].
- Management's forward-looking statements are based on assumptions such as ability to generate cash flow from operations and general economic conditions [sec_mda · as of 2026-08-07].
What works
- Canopy Growth holds a strong cash position of $336.6M as of 2026-06-30, providing liquidity for operations and strategic initiatives [sec].
- The company has a diverse product portfolio and global presence, positioning it as a leading cannabis company [sec_mda · as of 2026-02-06].
What to weigh
- The company reported a net loss of $14.6M for the period ended 2026-06-30, indicating ongoing profitability challenges [sec].
- Canopy Growth operates in a highly regulated and evolving industry, with risks related to regulatory changes and market conditions [sec_mda · as of 2026-08-07].
- The company carries significant debt of $269.0M as of 2026-06-30, which may impact financial flexibility [sec].
From the filings
Quoted directly from source documents.
Canopy Growth is a world-leading cannabis company
“We are a world-leading cannabis company which produces, distributes, and sells a diverse range of cannabis and cannabis related products.”
SEC MD&A · February 6, 2026
The company faces risks and uncertainties in its industries
“The industries in which we conduct our business involve risks and uncertainties that are subject to change based on various factors”
SEC MD&A · August 7, 2026
Forward-looking statements are based on material assumptions
“The forward-looking statements contained herein are based upon certain material assumptions, including: (i) management's perceptions of historical trends, current conditions and expected future developments; (ii) our ability to generate cash flow from operations; (iii) general economic, financial market, regulatory and political conditions in which we operate”
SEC MD&A · August 7, 2026
Catalyst timeline
- 2026-11-01 · Phase3_Topline — An open-label, single-arm, historically controlled, prospective, multi-center Phase III study to evaluate a product candidate; topline results are expected.
Risks & what to watch (4)›
Key risks
- Regulatory and legal risks — The cannabis industry is subject to evolving regulations in Canada and internationally, which could impact operations [sec_mda · as of 2026-08-07].
- Profitability and net loss — The company reported a net loss of $14.6M for the period ended 2026-06-30, indicating ongoing profitability challenges [sec].
- Debt and financial leverage — Total debt of $269.0M as of 2026-06-30 may constrain financial flexibility and increase interest costs [sec].
- Market and competitive risks — The company operates in a competitive market with imprecise data on market positions and shares [sec_mda · as of 2026-08-07].
What to watch
- Upcoming Phase 3 topline results on 2026-11-01, which could impact the company's pipeline and valuation [catalyst].
- Future earnings reports and financial performance, particularly revenue and net income trends [sec].
- Regulatory developments in key markets, including potential changes in cannabis laws [sec_mda · as of 2026-08-07].
Sources: Catalysts · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Canopy Growth Corp through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Canopy Growth Corp facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
46.5 months
OCF -$25M · Net income -$15M
No tracked pipeline phase
No tracked pipeline candidates
1 upcoming, next in ~63d
0 buys · 11 sells (180d)
Runway
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
221
Total value held
$25.0M
| Holder | Shares | Value |
|---|---|---|
| citadel advisors llc | 3,237,328 | $3.1M |
| susquehanna international group, llp | 2,720,976 | $2.6M |
| jane street group, llc | 2,007,412 | $1.9M |
| morgan stanley | 1,969,640 | $1.9M |
| lazard asset management llc | 1,807,986 | $1.7M |
| goldman sachs group inc | 1,263,602 | $1.2M |
| sig north trading, ulc | 1,228,993 | $1.2M |
| royal bank of canada | 975,967 | $927K |
| millennium management llc | 867,559 | $823K |
| sullivan wood capital management llc | 854,285 | $811K |
Showing top 10 of 221 institutional holders of Canopy Growth Corp. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 6.0%
- Days to cover
- 1.8
- Shares short
- 25,530,783
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CGC short interestGovernance
Frequently asked questions
What is the AI investment thesis for Canopy Growth Corp?
Canopy Growth Corp is a world-leading cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products, with a focus on the Canadian and international markets.
What is Canopy Growth Corp's next catalyst?
Canopy Growth Corp's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: An Open-Label, Single-Arm, Historically Controlled, Prospective, Multi-Center Phase III Study to Eva" — expected November 1, 2026.
Who is the CEO of Canopy Growth Corp?
Mr. Luc Mongeau is the chief executive officer of Canopy Growth Corp (CGC).
Where is Canopy Growth Corp headquartered?
Canopy Growth Corp (CGC) is headquartered in Smiths Falls, ON, Canada.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.